Normal view MARC view ISBD view

Early Leaflet Thickening, Durability and Bioprosthetic Valve Failure in TAVR. [Review]

MedStar author(s):

Citation: Interventional Cardiology Clinics. 10(4):531-539, 2021 10.PMID: 34593115Institution: MedStar Heart & Vascular Institute | MedStar Washington Hospital CenterDepartment: Interventional Cardiology FellowshipForm of publication: Journal ArticleMedline article type(s): Journal Article | ReviewSubject headings: *Bioprosthesis | *Heart Valve Prosthesis | *Transcatheter Aortic Valve Replacement | Humans | Prosthesis Failure | Treatment OutcomeYear: 2021 ISSN:

2211-7458

Name of journal: Interventional cardiology clinicsAbstract: All bioprosthetic valves, both surgical and transcatheter, have a finite lifespan before their leaflets inevitably degenerate, leading to stenosis or regurgitation. As younger, low-risk patients receive a transcatheter aortic valve, it is expected that they will most likely outlive their bioprosthetic valve. The heterogeneity of studies regarding surgical valve durability makes the interpretation of the data challenging. Leaflet thickening is seen in transcatheter heart valves but currently there is no evidence that it leads to premature valve deterioration or clinical events. Standardized definitions of structural valve deterioration should allow for comparisons between future clinical trials to assess the durability of different transcatheter heart valves. Copyright (c) 2021 Elsevier Inc. All rights reserved.All authors: Case BC, Khan JM, Rogers TOriginally published: Interventional Cardiology Clinics. 10(4):531-539, 2021 Oct.Fiscal year: FY2022Fiscal year of original publication: FY2022Digital Object Identifier:

https://dx.doi.org/10.1016/j.iccl.2021.05.005

Date added to catalog: 2021-11-01

Holdings ( 1 )
Title notes ( 2 )

Holdings
Item type	Current library	Collection	Call number	Status	Date due	Barcode
Journal Article	MedStar Authors Catalog	Article	34593115	Available		34593115

All bioprosthetic valves, both surgical and transcatheter, have a finite lifespan before their leaflets inevitably degenerate, leading to stenosis or regurgitation. As younger, low-risk patients receive a transcatheter aortic valve, it is expected that they will most likely outlive their bioprosthetic valve. The heterogeneity of studies regarding surgical valve durability makes the interpretation of the data challenging. Leaflet thickening is seen in transcatheter heart valves but currently there is no evidence that it leads to premature valve deterioration or clinical events. Standardized definitions of structural valve deterioration should allow for comparisons between future clinical trials to assess the durability of different transcatheter heart valves. Copyright (c) 2021 Elsevier Inc. All rights reserved.

English